Saniona’s CEO to BioStock: “SAN2355 is a highly promising candidate for commercialization”
Saniona has announced significant progress in the preclinical development of the epilepsy drug candidate SAN2355 to treat focal-onset seizures. BioStock talked to CEO Thomas Feldthus to learn more.
Read the full interview with Thomas Feldthus at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/